Abstract A42: EphB2 a potential therapeutic target for pediatric medulloblastoma
Notice bibliographique
Résumé
Abstract Aim: Medulloblastoma (MB) is the most frequent malignant brain tumor to occur in children and remains the leading cause of cancer-related mortality in childhood. The current standard of care for patients with MB includes surgical resection and radiation therapy followed by high-dose chemotherapy. Overall survival rates have reached 70%, but the outcome for young children, especially infants, is worse. Those who do survive suffer from long-term therapy-induced side effects. Thus, more effective and less toxic therapies are needed. Eph family receptors predominantly function during embryonic development and are typically either not expressed or expressed at very low levels in normal healthy tissues. However, it is now established that many Eph receptors are re-expressed and functional in human cancers, making them attractive, relatively tumor-specific targets. Thus, in MB anti-Eph therapy has the potential to target tumor cells and not normal brain, reducing off-target toxicity and potentially increasing response rates. We have generated compelling preliminary data showing that EphB2 is functional and overexpressed in pediatric MB. We now propose to extend these studies and validate antibody-based strategies to target this receptor. Methods: 1. EphB receptor expression was characterized using a number of approaches: RNA (RNASeq and QPCR), protein (flow cytometry and Western blot) and receptor localization by immunofluorescence in MB ATCC lines, primary lines, and patient tissue. 2. To better understand the function of the EphB2, gene expression was downregulated using shRNA in primary MB cell line models. Following EphB downregulation, we assessed in vitro growth and cell death induction and tumor-forming capacity using orthotopic MB intracranial xenografts. Moreover, following EphB activation, using soluble ligand we assessed in vitro growth via direct cell count and MTT assay, cell migration via scratch assay, and cell death induction via Annexin V staining. Following EphB inhibition, using peptide strategies we assessed in vitro growth, cell migration, and cell death induction. Results: Our study shows that EphB2 is both functional and highly expressed in MB. Furthermore, EphB2 appears to be expressed in a subtype-specific manner. We further confirmed our expression studies using the MB Advanced Genomics International Consortium (MAGIC) dataset. The EphB2 high-affinity ligands ephrinB1/B2-Fc were used to induce kinase activation. Following receptor activation, we observed reduced tumor cell proliferation and invasion in vitro. EphB2 receptor blocking studies, using the SNEW blocking peptide, effectively inhibited kinase phosphorylation and subsequently FAK phosphorylation. Most importantly, the small peptide rescues MB cell growth upon ephrin B ligand stimulation, indicating the specific mitogenic capacity of this receptor. Conclusion: In summary, this study furthers our understanding of EphB2 expression and function in MB and paves the way for future receptor-targeting studies in MB. Citation Format: Yuchen Li, Carolin Offenhauser, Rochelle D’Souza, Seckin Akgul, Bryan W. Day. EphB2 a potential therapeutic target for pediatric medulloblastoma [abstract]. In: Proceedings of the AACR Special Conference on the Advances in Pediatric Cancer Research; 2019 Sep 17-20; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Res 2020;80(14 Suppl):Abstract nr A42.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,001 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».